
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure is a gene therapy company with a strong pipeline focused on diseases with high unmet medical need, such as HD and hemophilia. The recent data update for its CNS pillar, AMT-260, is a positive sign for the company, with a 79-100% decline in disabling seizures in the first cohort of patients. The company also has a strong collaboration with Bristol Myers Squibb and a healthy cash runway, although there are risks associated with clinical development and commercialization.
Bears say
uniQure is a gene therapy company with speculative risk for investors due to commercial launch delays, potential competition, and the unpredictability of future revenues and expenses. Despite the potential for material upside with its Huntington's disease treatment and strong pipeline of gene therapies, there are risks such as regulatory uncertainties and failure to demonstrate sustained efficacy in trials. The recent run in the stock price aligns with this optimism but heightened gross-to-net and projected costs for AMT-130 could limit profitability, leading to a lower price target of $50 per share.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares